Research
Cellular
Gastrointestinal adverse events were more common with oral semaglutide than with placebo (74.0% vs. 42.2%).
Clinicians should monitor for gastrointestinal side effects in patients taking oral semaglutide.
StrongSupportsmedium confidence
Gastrointestinal adverse events were more common with oral semaglutide than with placebo (74.0% vs. 42.2%).
Why this rating
Based on a large randomized controlled trial design.
Source
Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity
Sean Wharton et al. · New England Journal of Medicine · 2025
DOI 10.1056/nejmoa2500969
rct · n=307Cited 52×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Oral semaglutide at a dose of 25 mg once daily resulted in a mean reduction in body weight of -13.6% from baseline to week 64.Strong
- Participants in the oral semaglutide group were significantly more likely to achieve body-weight reductions of 5% or more, 10% or more, 15% or more, and 20% or more compared to the placebo group.Strong
Related findings · Cellular
- Athletes aiming to reduce fat mass and preserve FFM should consume protein intakes in the range of ∼1.8-2.7 g kg(-1) d(-1).Strong
- A minimum daily protein intake of ≥1.6 g/kg is necessary to observe significant improvements in muscle mass from whey protein supplementation.Strong
- Most athletes ideally need 1.2 to 2.0 grams/kg of body weight/day of protein, preferably split across 3-4 meals.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →